CompletedEarly Phase 1

Defining and Treating Depression-related Asthma

United States39 participantsStarted 2016-09-09

Plain-language summary

Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression. The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.

Who can participate

Age range7 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of asthma * Decreased lung volumes for age/height/race (FEV1 \<80% predicted or ratio of FEV1 to forced vital capacity (FVC) \< 85%) on day of study visit assessed by spirometry. Exclusion Criteria: * Severely developmentally delayed patients, or those who suffer from other severe cognitive impairment not allowing them to perform spirometry or participate in study instruments. * Patients who are pregnant or nursing. * Patients with significant cardiopulmonary disease other than asthma, including cystic fibrosis, alpha-1-antitrypsin deficiency, interstitial lung disease, tracheo-/bronchomalacia, or cyanotic congenital cardiac defect. * Patients with glaucoma, myasthenia gravis, or bladder neck obstruction (anticholinergics can worsen these conditions). * Patients currently taking another anticholinergic medication

What they're measuring

FEV1 Percent Change Post-ipratropium

Timeframe: Baseline and 30 minutes

Trial details

NCT IDNCT04617015

SponsorState University of New York at Buffalo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-03-11

Results submitted2025-10-06

View on ClinicalTrials.gov More Asthma trials